NBI-921352 is a potent, highly selective Nav1.6 sodium channel inhibitor being developed to treat pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other potential indications, including adult focal epilepsy.
For research use only. We do not sell to patients.
Name | NBI-921352 |
---|---|
Iupac Chemical Name | Benzenesulfonamide, 2-fluoro-5-methyl-4-(methyl((3S)-1-(phenylmethyl)-3-pyrrolidinyl)amino)-N-4-thiazolyl- |
Synonyms | NBI-921352; NBI921352; NBI 921352; XEN901; XEN 901; XEN-901; Zandatrigine |
Molecular Formula | C22H25FN4O2S2 |
Molecular Weight | 460.59 |
Smile | O=S(C1=CC(C)=C(N(C)[C@@H]2CN(CC3=CC=CC=C3)CC2)C=C1F)(NC4=CSC=N4)=O |
InChiKey | UCSHINHOAVARGQ-SFHVURJKSA-N |
InChi | InChI=1S/C22H25FN4O2S2/c1-16-10-21(31(28,29)25-22-14-30-15-24-22)19(23)11-20(16)26(2)18-8-9-27(13-18)12-17-6-4-3-5-7-17/h3-7,10-11,14-15,18,25H,8-9,12-13H2,1-2H3/t18-/m0/s1 |
CAS Number | 2154406-04-7 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | Solid powder |
---|---|
Purity | 98% Min. |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Solubility | Soluble in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |
1: Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development. Epilepsia. 2020 Nov;61(11):2340-2364. doi: 10.1111/epi.16725. Epub 2020 Nov 14. PMID: 33190243.